Amicus Therapeutics Accounts Payable

Amicus Therapeutics (FOLD) currently reports a accounts payable of $29M as of December 2025. That compares with $13M in the prior-year period — up 121.1% year over year. Use the charts on this page to explore Amicus Therapeutics's accounts payable history and peer comparisons.

Amicus Therapeutics's accounts payable increased from $13M to $29M — a 121.1% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amicus Therapeutics reported $29M in accounts payable as of December 2025. That compares with $13M in the prior-year period — up 121.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Amicus Therapeutics, and consider following FOLD for alerts when major investors trade the stock.

Amicus Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FOLD with unrelated industries.